USA
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from Dermaliq Therapeutics.
Munich, Germany and Wilmington, DE, U.S., 28 May 2025 – DEBRA Research gGmbH, a global nonprofit organization dedicated to advancing research and drug development for those affected by Epidermolysis Bullosa (EB), and Dermaliq Therapeutics, Inc., a clinical-stage dermatology innovator company developing next-generation topical therapies, today announced a strategic, non-exclusive collaboration to advance cutaneous drug delivery into the skin for EB. Initially, the partners will focus on improving wound-healing and anti-itch therapies, plus developing prophylactic therapies for people suffering from EB. As part of the agreement, DEBRA Research has also made a strategic investment in Dermaliq.
This is the News section of the company profile page for Dermaliq Therapeutics on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
